What is Zacks Research’s Estimate for NKTR FY2024 Earnings?

Nektar Therapeutics (NASDAQ:NKTR) – Zacks Research lifted their FY2024 EPS estimates for Nektar Therapeutics in a research report issued on Monday, January 6th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will earn ($0.76) per share for the year, up from their previous estimate of ($0.80). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.71) per share. Zacks Research also issued estimates for Nektar Therapeutics’ Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.89) EPS.

Several other equities research analysts have also recently weighed in on the company. BTIG Research reiterated a “buy” rating and set a $4.00 price target on shares of Nektar Therapeutics in a research report on Monday, September 30th. Piper Sandler began coverage on Nektar Therapeutics in a report on Monday, November 4th. They issued an “overweight” rating and a $7.00 price target on the stock. HC Wainwright began coverage on Nektar Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $6.50 price objective for the company. Finally, B. Riley began coverage on shares of Nektar Therapeutics in a report on Wednesday. They set a “buy” rating and a $4.00 price objective for the company. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Nektar Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $4.08.

Nektar Therapeutics Stock Performance

Shares of NASDAQ NKTR opened at $1.14 on Thursday. The stock has a fifty day moving average of $1.09 and a 200-day moving average of $1.21. The stock has a market cap of $210.28 million, a PE ratio of -1.36 and a beta of 0.59. Nektar Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $1.93.

Insider Buying and Selling at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 46,995 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $1.01, for a total transaction of $47,464.95. Following the completion of the transaction, the chief executive officer now owns 1,195,710 shares in the company, valued at $1,207,667.10. This represents a 3.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Andrew Wilson sold 33,402 shares of Nektar Therapeutics stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the transaction, the insider now directly owns 351,892 shares of the company’s stock, valued at approximately $316,702.80. This trade represents a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 155,575 shares of company stock valued at $149,878 in the last quarter. Company insiders own 3.71% of the company’s stock.

Hedge Funds Weigh In On Nektar Therapeutics

Large investors have recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new stake in Nektar Therapeutics in the second quarter worth about $29,000. Valence8 US LP purchased a new position in Nektar Therapeutics during the third quarter valued at approximately $34,000. Intech Investment Management LLC bought a new position in Nektar Therapeutics in the third quarter worth approximately $41,000. XTX Topco Ltd bought a new stake in Nektar Therapeutics during the 3rd quarter valued at $46,000. Finally, Erste Asset Management GmbH purchased a new position in shares of Nektar Therapeutics in the 3rd quarter valued at $61,000. 75.88% of the stock is owned by hedge funds and other institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.